Local effects of vaginally administered estrogen therapy: A review

Journal of Pelvic Medicine and Surgery

Volumn 15, Issue 3, 2009, Pages 105-114

  Krause, Megan ^a   Wheeler II, Thomas L ^b   Snyder, Thomas E ^a   Richter, Holly E ^c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Menopause; Quality of life; Vaginal atrophy; Vaginal estrogen

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; PLACEBO;

DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DYSURIA; ENDOMETRIUM; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; MENOPAUSE; NOCTURIA; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; URETHRITIS; URINARY TRACT INFECTION; URINE INCONTINENCE; VAGINA ATROPHY; VAGINA RING;

EID: 68049128298     PISSN: 15425983     EISSN: None     Source Type: Journal    
DOI: 10.1097/SPV.0b013e3181ab4804     Document Type: Review

References (54)

1. Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92:722-727.
2. Position Statement. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause J North Am Menopause Soc. 2007;14:357-369.
3. Krause M, Wheeler T, Richter H, et al. Systemic effects of vaginally administered estrogen therapy. In press.
4. Alexander NJ, Baker E, Kaptein M, et al. Why consider vaginal drug administration? Fertil Steril. 2004;82:1-12.
5. DeZiegler D, Bulletti C, DeMonstier B, et al. The first uterine pass effect. Ann NY Acad Sci. 1997;828:291-299.
6. Notelovitz M, Funk S, Nanavati N, et al. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99:556-562.
7. Femring Package Insert. Available at: http://www.fda.gov/cder/foi/label/ 2005/21367s002lbl.pdf.
8. Speroff L; the United States VR Investigator Group. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol. 2003;102:823-834.
9. Estring Package Insert. Available at: http://www.pfizer.com/files/ products/uspi-estring.pdf.
10. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180:1072-1079.
11. Bachmann GA. Vulvovaginal complaints. In: Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. New York, NY: Raven Press; 1994:137-142.
12. Iosif CS, Batra S, Ek A, et al. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol. 1981;141:817-820.
13. Batra SC, Iosif LS. Progesterone receptors in the female lower urinary tract. J Urol. 1987;138:1301-1304.
14. Blakeman PJ, Hilton P, Bulmer JN. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to estrogen status. BJU Int. 2000;86:32-38.
15. Iosif CS, Bekassy Z. Prevalence of genitor-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand. 1984;63:257-260.
16. Barlow DH, Samsioe G, van Geelan JM. A study of European women's experience of the problems of urogenital aging and its management. Maturitas. 1997;27:239-247.
17. Youngblood VH, Tomlin EM, Davis JB. Senile urethritis in women. J Urol. 1957;78:150-152.
18. Long CY, Liu CM, Hsu SC, et al. A randomized and comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril. 2006;85:155-160.
19. Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293:935-948.
20. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1994;83:12-18.
21. Bhatia NN, Bergman A, Karam MM. Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol. 1989;160:176-181.
22. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol. 2001;97:116-120.
23. Deleted in proof.
24. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137:805-813.
25. Bygdeman M, Swahn ML. Replens versus dienstrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259-263.
26. Moebrer B, Hextal A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev. 2003;CD001405.
27. Lose G, Englev E. Oestradiol releasing vaginal ring versus oestriol pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG. 2000;107:1029-1034.
28. Simunic V, Banovic I, Ciglar S, et al. Local estrogen treatment in patients with urogential symptoms. Int J Gynaecol Obstet. 2003;82:187-197.
29. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med. 2005;2(suppl 3):154-165.
30. Alexander JL, Kotz K, Dennerstein L, et al. The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause J North Am Menopause Soc. 2004;11:749-765.
31. Longcope C. Hormone dynamics at the menopause. Ann NY Acad Sci. 1990;592:21-30.
32. Zumoff B, Strain GW, Miller LK, et al. Twenty-fourhour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab. 1995;80:1429-1430.
33. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, et al. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2000;85:645-651.
34. Sarrel PM. Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause (Erratum in: J Women's Health Gender Based Med. 2001;10:91). J Women's Health Gender Based Med. 2000;9(suppl 1):S25-S32.
35. Cutler WB, Garcia CR, McCoy N. Perimenopausal sexuality. Arch Sex Behav. 1987;16:225-234.
36. Willhite LA, O'Connell MB. Urogenital atrophy. Prevention and treatment. Pharmacotherapy. 2001;21:464-480.
37. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005;105:944-952.
38. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause J North Am Menopause Soc. 2004;11:120-130.
39. Freedman MA. Sexuality and the menopausal women. Contemp Obstet Gynecol. 2000;(suppl):1-22.
40. Semmens JP, Tsai CC, Semmens EC, et al. Effects of estrogen therapy on vaginal physiology during menopause. Obstet Gynecol. 1985;66:15-18.
41. Berman JR, Goldstein I. Female sexual dysfunction. Urol Clin North Am. 2001;28:405-416.
42. McCoy NL. Female sexuality during aging. In: Hof PR, Mobbs CV, eds. Functional Neurobiology of Aging. New York, NY: Academic Press; 2001:769-779.
43. Berman JR, Berman LA, Werbin TJ, et al. Clinical evaluation of female sexual function: effects of age and estrogen status on subjective and physiologic sexual responses. Int J Impot Res. 1999;11:S31-S38.
44. Gast M, Freedman M, Vieweg A, et al. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause. 2009;16:1-10.
45. Cayan F, Dilek U, Pata O, et al. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. J Sex Med. 2008;5:132-138.
46. Ashcroft GS, Ashworth JJ. Potential role of estrogens in wound healing. Am J Clin Dermatol. 2003;4:737-743.
47. Cicinelli E, DeZiegler D, Morgese S, et al. "First uterine pass effect" is observed when estradiol is placed in the upper but not lower third of the vagina. Fertil Steril. 2004;81:1414-1416.
48. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1996;275:370-375.
49. Vagifem [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals Inc; 2003.
50. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005;8:83-92.
51. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17β-estradiol in elderly women. Am J Obstet Gynecol. 2002;186:944 -947.
52. Maruo T, Mishell DR, Ben-Chetrit A, et al. Vaginal rings delivering progesterone and estradiol may be a new method of hormone replacement therapy. Fertil Steril. 2002;78:1010-1016.
53. MacLennan AH, Sturdee DW. Is endometrial monitoring required with the use of long-term unopposed vaginal estrogen? Climacteric. 2006;9:321-322.
54. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane Database Syst Rev. 2003:CD001500.